Prediction of bortezomib-induced peripheral neuropathy with the R–R interval variation of the electrocardiogram in plasma cell myeloma: a retrospective study

References

• McKenna RW, Kyle RA, Kuehl WM, et al. Plasma cell neoplasms In: Swerdlow SH, Campo E, Harris NL, et al. editors. World Health Organization classification of tumors of haematopoietic and lymphoid tissues. Lyon (France): IARC Press; 2017. p. 241–258.
   Google Scholar
• Vangsted A, Klausen TW, Vogel U. Genetic variations in multiple myeloma II: association with effect of treatment. Eur J Haematol. 2012;88(2):93–117.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, et al. VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906–917.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. JCO. 2006;24(19):3113–3120.
   PubMed Web of Science ®Google Scholar
• Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431–440.
   PubMed Web of Science ®Google Scholar
• Delforge M, Bladé J, Dimopoulos MA, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol. 2010;11(11):1086–1095.
   PubMed Web of Science ®Google Scholar
• Cata JP, Weng HR, Burton AW, et al. Quantitative sensory findings in patients with bortezomib-induced pain. J Pain. 2007;8(4):296–306.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Gilardini A, Canta A, et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol. 2007;204(1):317–325.
   PubMed Web of Science ®Google Scholar
• Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127(2):165–172.
   PubMed Web of Science ®Google Scholar
• Gidal BE. New and emerging treatment options for neuropathic pain. Am J Manag Care. 2006;12(9 Suppl):S269–S78.
   PubMed Web of Science ®Google Scholar
• Hughes RA. Peripheral neuropathy. BMJ. 2002;324(7335):466–469.
   PubMedGoogle Scholar
• Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. JCO. 2010;28(30):4621–4629.
   PubMed Web of Science ®Google Scholar
• Corthals SL, Kuiper R, Johnson DC, et al. Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients. Haematologica. 2011;96(11):1728–1732.
   PubMed Web of Science ®Google Scholar
• Broyl A, Corthals SL, Jongen JL, et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. 2010;11(11):1057–1165.
   PubMed Web of Science ®Google Scholar
• Murray A, Ewing DJ, Campbell IW, et al. RR interval variations in young male diabetics. Br Heart J. 1975;37(8):882–885.
   PubMedGoogle Scholar
• The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749–757.
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BG, et al. International Staging System for multiple myeloma. JCO. 2005;23(15):3412–3420.
   PubMed Web of Science ®Google Scholar
• Corbin ZA, Nguyen-Lin A, Li S, et al. Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome. J Neurooncol. 2017;132(3):439–446.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Delforge M, Facon T, et al. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia. 2018;32(7):1542–1560.
   PubMed Web of Science ®Google Scholar
• Salahuddin L, Cho J, Jeong MG, et al. Ultra short term analysis of heart rate variability for monitoring mental stress in mobile settings. Conf Proc IEEE Eng Med Biol Soc. 2007;2007:4656–4659.
   PubMedGoogle Scholar
• Badros A, Goloubeva O, Dalal JS, et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer. 2007;110(5):1042–1049.
   PubMed Web of Science ®Google Scholar
• Velasco R, Petit J, Clapés V, et al. Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients. J Peripher Nerv Syst. 2010;15(1):17–25.
   PubMed Web of Science ®Google Scholar
• Hashimoto N, Yokoyama K, Sadahira K, et al. Itraconazole may increase the risk of early-onset bortezomib-induced peripheral neuropathy. Int J Hematol. 2012;96(6):758–763.
   PubMed Web of Science ®Google Scholar
• Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010;116(23):4745–4753.
   PubMed Web of Science ®Google Scholar
• Minarik J, Pavlicek P, Pour L, et al. Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy. PLoS One. 2015;10(4):e0123866.
   PubMed Web of Science ®Google Scholar
• Reeder CB, Reece DE, Kukreti V, et al. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood. 2010;115(16):3416–3417.
   PubMed Web of Science ®Google Scholar
• Agathocleous A, Rohatiner A, Rule S, et al. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia. Br J Haematol. 2010;151(4):346–353.
   PubMed Web of Science ®Google Scholar